Literature DB >> 29109492

Yes, We Are Still Talking about Cylosporin vs. Infliximab in Steroid Resistant Acute Severe Ulcerative Colitis.

Charles N Bernstein1, Asher Kornbluth2.   

Abstract

The Spanish IBD Registry (ENEIDA) is reporting in this issue of the Journal on a retrospective assessment of outcomes of cyclosporine use and infliximab use to treat steroid refractory acute severe ulcerative colitis (SR-ASUC) between 1989 and 2013. Overall, they found similar outcomes in terms of 3 month and 1 year colectomy rates. Serious adverse events were lower in cyclosporine users. While this study does not meet the standard of a prospective randomized controlled trial, it does remind us that cyclosporine can be effective in (SR-ASUC) and should be considered in those who have already failed antibody to tumor necrosis factor therapy or as a bridge to immunomodulators that have a slower onset of action.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29109492     DOI： 10.1038/ajg.2017.282

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


  11 in total

1.  Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: pragmatic randomised Trial and economic evaluation (CONSTRUCT).

Authors:  John G Williams; M Fasihul Alam; Laith Alrubaiy; Clare Clement; David Cohen; Michelle Grey; Mike Hilton; Hayley A Hutchings; Mirella Longo; Jayne M Morgan; Frances L Rapport; Anne C Seagrove; Alan Watkins
Journal:  Health Technol Assess       Date:  2016-06       Impact factor: 4.014

Review 2.  Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids.

Authors:  Neeraj Narula; John K Marshall; Jean-Frederic Colombel; Grigorios I Leontiadis; John G Williams; Zack Muqtadir; Walter Reinisch
Journal:  Am J Gastroenterol       Date:  2016-02-09       Impact factor: 10.864

3.  Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab.

Authors:  D Laharie; A Bourreille; J Branche; M Allez; Y Bouhnik; J Filippi; F Zerbib; G Savoye; L Vuitton; J Moreau; A Amiot; J Cosnes; E Ricart; O Dewit; A Lopez-Sanroman; M Fumery; F Carbonnel; G Bommelaer; B Coffin; X Roblin; G van Assche; M Esteve; M Farkkila; J P Gisbert; P Marteau; S Nahon; M de Vos; J Lambert; J Y Mary; E Louis
Journal:  Gut       Date:  2017-01-04       Impact factor: 23.059

4.  Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

Authors:  Gunnar Järnerot; Erik Hertervig; Ingalill Friis-Liby; Lars Blomquist; Per Karlén; Christer Grännö; Mogens Vilien; Magnus Ström; Ake Danielsson; Hans Verbaan; Per M Hellström; Anders Magnuson; Bengt Curman
Journal:  Gastroenterology       Date:  2005-06       Impact factor: 22.682

5.  Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis.

Authors:  Gert Van Assche; Geert D'Haens; Maja Noman; Séverine Vermeire; Martin Hiele; Katrien Asnong; Joris Arts; Andre D'Hoore; Freddy Penninckx; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2003-10       Impact factor: 22.682

6.  Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis.

Authors:  Johannan F Brandse; Gijs R van den Brink; Manon E Wildenberg; Desiree van der Kleij; Theo Rispens; Jeroen M Jansen; Ron A Mathôt; Cyriel Y Ponsioen; Mark Löwenberg; Geert R A M D'Haens
Journal:  Gastroenterology       Date:  2015-04-25       Impact factor: 22.682

7.  Cyclosporine in severe ulcerative colitis refractory to steroid therapy.

Authors:  S Lichtiger; D H Present; A Kornbluth; I Gelernt; J Bauer; G Galler; F Michelassi; S Hanauer
Journal:  N Engl J Med       Date:  1994-06-30       Impact factor: 91.245

8.  Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.

Authors:  David Laharie; Arnaud Bourreille; Julien Branche; Matthieu Allez; Yoram Bouhnik; Jerome Filippi; Frank Zerbib; Guillaume Savoye; Maria Nachury; Jacques Moreau; Jean-Charles Delchier; Jacques Cosnes; Elena Ricart; Olivier Dewit; Antonio Lopez-Sanroman; Jean-Louis Dupas; Franck Carbonnel; Gilles Bommelaer; Benoit Coffin; Xavier Roblin; Gert Van Assche; Maria Esteve; Martti Färkkilä; Javier P Gisbert; Philippe Marteau; Stephane Nahon; Martine de Vos; Denis Franchimont; Jean-Yves Mary; Jean-Frederic Colombel; Marc Lémann
Journal:  Lancet       Date:  2012-10-10       Impact factor: 79.321

9.  Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.

Authors:  Remo Panaccione; Subrata Ghosh; Stephen Middleton; Juan R Márquez; Boyd B Scott; Laurence Flint; Hubert J F van Hoogstraten; Annie C Chen; Hanzhe Zheng; Silvio Danese; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2014-02       Impact factor: 22.682

10.  Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study.

Authors:  I Ordás; E Domènech; M Mañosa; V García-Sánchez; E Iglesias-Flores; M Peñalva; A Cañas-Ventura; O Merino; F Fernández-Bañares; F Gomollón; M Vera; A Gutiérrez; E Garcia-Planella; M Chaparro; M Aguas; E Gento; F Muñoz; M Aguirresarobe; C Muñoz; L Fernández; X Calvet; C E Jiménez; M A Montoro; A Mir; M L De Castro; M F García-Sepulcre; F Bermejo; J Panés; M Esteve
Journal:  Am J Gastroenterol       Date:  2017-07-04       Impact factor: 10.864
View more
  1 in total

Review 1.  Optimal Management of Acute Severe Ulcerative Colitis (ASUC): Challenges and Solutions.

Authors:  Tom Holvoet; Triana Lobaton; Pieter Hindryckx
Journal:  Clin Exp Gastroenterol       Date:  2021-03-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.